Trial Profile
A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ebselen (Primary)
- Indications Noise-induced hearing loss; Sensorineural hearing loss
- Focus Adverse reactions
- Sponsors Sound Pharmaceuticals
- 29 Mar 2014 New trial record